Literature DB >> 17343723

Electrophysiologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertrophic cardiomyopathy.

Yong-Mei Cha1, Bernard J Gersh, Barry J Maron, Giuseppe Boriani, Paolo Spirito, David O Hodge, Peggy L Weivoda, Jane M Trusty, Paul A Friedman, Stephen C Hammill, Robert F Rea, Win-Kuang Shen.   

Abstract

INTRODUCTION: Our objective was to determine features of ventricular tachyarrhythmias triggering appropriate implantable cardioverter-defibrillator (ICD) interventions in hypertrophic cardiomyopathy (HCM). METHODS AND
RESULTS: The study cohort was 68 high-risk HCM patients who received ICDs for primary sudden cardiac death prevention from 1995 to 2003. All episodes of sustained ventricular tachyarrhythmias identified by stored intracardiac electrograms were analyzed. Nine patients had 51 episodes of sustained ventricular tachyarrhythmic events that required device therapy (mean follow-up, 3.4 +/- 2.2 years; cumulative event rate, 3.2% per year): five had 47 episodes of monomorphic ventricular tachycardia (VT); four each had one episode of ventricular fibrillation (VF). Sinus tachycardia or atrial fibrillation was the initiating rhythm in five of nine patients and in 43 of 51 episodes of events. Of the 17 episodes of monomorphic VT detected in the VT zone, 16 (94%) were terminated by antitachycardia pacing. Thirty episodes of monomorphic VT were detected in the VF zone and were terminated by defibrillation.
CONCLUSION: Sustained monomorphic VT is common in a high-risk cohort with HCM. Sinus tachycardia is often the initiating rhythm, suggesting that high sympathetic drive may be proarrhythmic when a susceptible substrate is present. Antitachycardia pacing is highly effective in terminating VT in this patient population.

Entities:  

Mesh:

Year:  2007        PMID: 17343723     DOI: 10.1111/j.1540-8167.2007.00780.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  11 in total

1.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Saenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  J Interv Card Electrophysiol       Date:  2020-10       Impact factor: 1.900

2.  Global longitudinal strain and left atrial volume index improve prediction of appropriate implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy patients.

Authors:  Philippe Debonnaire; Joep Thijssen; Darryl P Leong; Emer Joyce; Spyridon Katsanos; Georgette E Hoogslag; Martin J Schalij; Douwe E Atsma; Jeroen J Bax; Victoria Delgado; Nina Ajmone Marsan
Journal:  Int J Cardiovasc Imaging       Date:  2014-02-06       Impact factor: 2.357

3.  Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events.

Authors:  Jeffrey P Moak; Eric S Leifer; Dorothy Tripodi; Saidi A Mohiddin; Lameh Fananapazir
Journal:  Pediatr Cardiol       Date:  2011-04-13       Impact factor: 1.655

Review 4.  Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy.

Authors:  Julian O M Ormerod; Michael P Frenneaux; Mark V Sherrid
Journal:  Nat Rev Cardiol       Date:  2016-07-14       Impact factor: 32.419

Review 5.  Risk Stratification in Hypertrophic Cardiomyopathy.

Authors:  Alexandros Klavdios Steriotis; Sanjay Sharma
Journal:  Eur Cardiol       Date:  2015-07

6.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Sáenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  Europace       Date:  2019-08-01       Impact factor: 5.214

Review 7.  Increased myofilament Ca2+-sensitivity and arrhythmia susceptibility.

Authors:  Sabine Huke; Björn C Knollmann
Journal:  J Mol Cell Cardiol       Date:  2010-01-22       Impact factor: 5.000

8.  Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice.

Authors:  Franz Baudenbacher; Tilmann Schober; Jose Renato Pinto; Veniamin Y Sidorov; Fredrick Hilliard; R John Solaro; James D Potter; Björn C Knollmann
Journal:  J Clin Invest       Date:  2008-11-20       Impact factor: 14.808

Review 9.  Hypertrophic cardiomyopathy: Can the noninvasive diagnostic testing identify high risk patients?

Authors:  Li Zhang; Obinna Mmagu; Liwen Liu; Dayuan Li; Yuxin Fan; Adrian Baranchuk; Peter R Kowey
Journal:  World J Cardiol       Date:  2014-08-26

10.  Exercise, heart and health.

Authors:  Gi-Byoung Nam
Journal:  Korean Circ J       Date:  2011-03-31       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.